This is a smoking cessation treatment study. A novel smoking cessation treatment will be provided to half of the participants in the study. All study participants will receive standard smoking cessation therapy including counseling nicotine patches. Smokers will also be asked to provide daily logs of smoking behavior over the course of 3-days of training, and provide an additional 28 days of daily diaries upon completion of the training period.

This is a smoking cessation treatment study. Patients who have a cancer or a suspected cancer who will undergo surgical removal of their cancer are eligible to participate in this study. A novel smoking cessation treatment will be provided to half of the participants in the study. All study participants will receive standard smoking cessation therapy including counseling and the nicotine patch.

The purpose of this study is to understand how different types of non-cigarette tobacco products affect the way smokers use tobacco products. There are three in-person visits and brief, daily electronic diaries across the two weeks of the study, and eligible individuals will be able to try a new type of tobacco product called a heated tobacco product.

This is a research study to find out if a smoking cessation medications, either varenicline or nicotine replacement products (patches or lozenges), are effective when given to smokers,remotely,as a one-time sample.

Participants will either receive a sample of varenicline, nicotine patches and lozenges, or neither. This will be decided randomly. Participants have a 50%chance of receiving varenicline, a 25% chance of receiving nicotine products, and a 25% chance of receiving neither. If the participant is assigned to a group that receives free samples, they will be mailed to them free of charge. There is no requirement to use them, and it is completely up to the participants. There is also no requirement to quit in this study.

The study lasts for six months, and will involve six total surveys. In addition, we ask that participants complete daily diaries (about 1 minute each) for the first 4 weeks of the study. Both varenicline and nicotine replacement products are well-established medications that help smokers quit.

This study is recruiting youth between the ages of 12 and 21 who use electronic cigarettes (e-cigs, vaping) and are interested in quitting. The purpose of this research study is to explore if youth vapers can quit using a smartphone application that delivers incentives. This study is completely remote (no in-person visits) with phone call visits and the use of a mobile app. If enrolled, participants will have brief weekly phone call visits for 4 weeks and a follow-up call on week 8. Participants will be encouraged to quit vaping during the study. Participants will be asked to submit selfie videos via the app providing saliva cotinine (by product of nicotine) samples to confirm that they have quit vaping.

The purpose of this project is to understand how different types of non-cigarette tobacco products affect the way smokers use tobacco products. Participants will complete three in-person visits. Prior to the second visit, they will be required not to smoke after midnight on the night before the visit. During the second visit, participants will sample a traditional cigarette and two e-cigarette e-liquids. Participants will answer questionnaires about each product they sample and then complete a preference assessment in which they choose between the products they sampled and their own cigarette. Finally, participants will take home a tobacco product they sampled to use ad libitum (1-week sampling). During the at-home baseline and sampling weeks, participants will complete electronic daily diaries cataloging their tobacco use. Biomarkers (i.e., expired carbon monoxide, cotinine) will corroborate self-reported indices of use. Participation will last approximately two weeks. E-cigarettes are likely less harmful than combustible cigarettes, but we are unsure how harmful, or how safe they might be. Side effects from using the e-cigarette are generally rare and mild, and may include: nausea, headache, heartburn, irritability, anxiety, headache, or trouble sleeping. There is no direct benefit for participating. Participation will aid researchers to determine how different types of tobacco products affect smoking behavior.

The US Food and Drug Administration (FDA) is beginning to regulate tobacco products in ways that promote the use of less harmful products, such as electronic cigarettes, among established adult smokers. In this study, we will evaluate whether using cigarette inserts that contain messages about lower harms form vaping vs smoking will be effective in getting smokers to switch from cigarettes to vaping. All participants will be given a JUUL starter kit and randomized to receive a 2 week supply of their preferred cigarette brand either without (control group) or with inserts that contain harm reduction messages (experimental group). We will evaluate whether the harm reduction messages influence attitudes and beliefs that are likely to promote smoking cessation and switching to e-cigarettes.

The goal of this research is to understand how different types of e-cigarettes affect tobacco use. Participants will either be assigned to a control group that does not receive an e-cigarette or be assigned to receive one of two different types of e-cigarettes to sample in the lab and at home. We will measure participants' smoking and smoke exposure during the study.

Nicotine addiction is a chronic, relapsing brain disorder and although it is the leading cause of preventable premature death in the US, ~20% of adults smoke and among those that try to quit, the majority relapse.Research suggest that nicotine addiction disrupts the working in the brain involved in motivation and reward. The overarching goal of this proposal is to utilize clinical neuroscience to investigate the effects of Mindfulness Oriented Recovery Enhancement (MORE) on modifying behavior to help treat nicotine addiction.

The purpose of this study is to better understand tobacco outcomes using a well-known stop smoking medication, varenicline (Chantix), and financial incentives with tobacco users. We are also interested in how cannabis/marijuana and tobacco interact during a tobacco quit attempt. All participants will receive tobacco cessation treatment (varenicline) for 12 weeks. This study will recruit adult tobacco users (ages 18-40) who are motivated to quit smoking cigarettes.